ABSTRACT − Hyaluronic acid (HA) is a biodegradable, biocompatible, non-toxic, non-immunogenic and non-inflammatory linear polysaccharide, which has been used for various medical applications including arthritis treatment, wound healing, ocular surgery, and tissue augmentation. Because of its mucoadhesive property and safety, HA has received much attention as a tool for drug delivery system development. It has been used as a drug delivery carrier in both nonparenteral and parenteral routes. The nonparenteral application includes the ocular and nasal delivery systems. On the other hand, its use in parenteral systems has been considered important as in the case of sustained release formulation of protein drugs through subcutaneous injection. Particles and hydrogels by various methods using HA and HA derivatives as well as by conjugation with other polymer have been the focus of many studies. Furthermore, the affinity of HA to the CD44 receptor which is overexpressed in various tumor cells makes HA an important means of cancer targeted drug delivery. Current trends and development of HA as a tool for drug delivery will be outlined in this review.
Hyaluronic acid (also called as Hyaluronan and Hyaluronate (HA) and Sodium Hyaluronate(SA) is sodium salt form of hyaluronic acid) is a biodegradable, biocompatible, and viscoelastic linear polysaccharide of a wide molecular weight range (1000 to 10,000,000 Da). It is composed of alternating disaccharide units of d-glucuronic acid and N-acetyl-d-glucosamine with (1→4) inter glycosidic linkage (Laurent, 1998) and is distributed throughout the extracellular matrix, connective tissues, and organs of all higher animals (Prestwich et al., 1998) . Metabolism of HA occurs through the enzymatic hydrolysis by hyaluronidase (HAase) which is present in various mammalian tissues . The HA molecule is readily soluble in water, producing a gel that behaves like a lubricant. It also adsorbs water, lending it hygroscopic and homeostatic properties . The viscosity of the HA gel is dependent upon a number of factors including the length of the chain (and by extension and the degree of entanglement), cross-linking, pH and chemical modification while the absolute concentration seems to be much less important (Varma et al., 1975; Park and Chakrabarti, 1978; Kobayashi et al., 1994) .
HA controls tissue hydration and exists in hydrated networks with collagen fibers in the extra-cellular matrix. It also constitutes the backbone of cartilage proteoglycan. Because of its unique physicochemical properties and various biological functions, HA and modified HA have been extensively investigated and widely used for pharmaceutical and medical applications, (Balazs and Denlinger, 1993; Illum et al., 1994; Hahn et al., 2004; Ohri et al., 2004) such as for arthritis treatment (Balazs and Denlinger, 1993) , ophthalmic surgery (Bothner and Wik, 1987) , drug development , and tissue engineering (West et al., 1985; Ohri et al., 2004) . HA is known to be involved in wound healing, promoting cell motility and differentiation during development (Laurent, 1998) . A number of strategies for the chemical modification of HA for improving its physicochemical properties through carboxyl and hydroxyl groups have been developed (Balazs and Leshchiner, 1987; Kuo et al., 1991; Illum et al., 1994; Luo et al., 2000; Hahn et al., 2004; Ohri et al., 2004) .
Recently, HA polymers have become the topic of interest for developing sustained drug delivery devices of peptide and protein drugs in subcutaneous formulations. Studies also suggested that a number of HA molecules may be used as gel preparations for ocular and nasal drug delivery (Le Bourlais et al., 1998) . In addition, HA has been used for targeting specific intracellular delivery of genes or anticancer drugs. Since the uptake of HA is known to be through the receptor-mediated endocytosis on specific receptors such as cluster determinant 44 (CD44) and receptor for hyaluronate-mediated motility (RHAMM), HA is usually conjugated or coated with the chemical drug or polymer to enhance therapeutic efficiency as well as to provide sustained release (SR) properties. The appli-J. Pharm. Invest., Vol. 40, No. Special issue (2010) cations of HA in the above mentioned drug delivery systems for both nonparentral and parenteral delivery will be discussed in the current review.
HA in Nonparenteral Delivery
The water solubility, viscoelasticity and biocompatibility of HA allow its application in nonparental delivery. Ocular and nasal delivery are two areas where HA has especially been widely used.
Ocular delivery HA has been used in ocular delivery due to its nonirritating property and high water-binding capacity. Its viscosity and pseudoplastic behavior providing mucoadhesive property can increase the ocular residence time. Various studies have been conducted with HA where an increase in biocompatibility as well as mucoadhesive property has been observed. For example, 1% pilocarpine solution dissolved in HA increased the 2-fold absorption of drug (Camber et al., 1987) , improving the bioavailability, and miotic response while extending the duration of action (Bucolo and Mangiafico, 1999) . In another study, HA allowed maintenance of 50 % of the drug activity up to 20 min after administration (Gurny et al., 1990) . Gentamicin bioavailability was also reported to be increased when formulated with a 0.25 % HA solution (Bernatchez, 1993) .
Moreover, films and microspheres have been prepared from various esters of HA. Methylprednisolone, either physically incorporated into the polymer matrix or chemically bound to the polymer backbone through an ester linkage resulted in an improved corneal bioavailability (Kyyrönen et al., 1992) . In addition, prednisolone using HA benzyl ester films through ocular delivery provided optimally sustained drug delivery (Hume et al., 1994) while ocular formulation of poly-ε-caprolactone (PCL) nanosphere coated with HA increased bioavailablity (Barbault-Foucher et al., 2002) . Recently, HA coated PCL/benzalkonium chloride nanospheres were able to achieve high levels of cyclosporine A (Cy A) in the cornea that was 10-15-fold higher than that achieved with Cy A solution in castor oil (Yenice et al., 2008) .
Nasal delivery
The nasal route has been explored as an alternative for systemic drug delivery for decades. This is because rapid absorption is possible in the nasal cavity due to its large surface area and relatively high blood flow while being able to avoid hepatic first-pass elimination (Turker et al., 2004; Ugwoke et al., 2005) . However, these nasal formulations still need to (Bourguignon et al., 2000; Dollo et al., 2004) Dermal • Surface hydration and film formation enhance the permeability of the skin to topical drugs • Promotes drug retention and localization in the epidermis • Exerts an anti-inflammatory action (medium-and highmolecular-weight HA) (Tammi et al., 1988; Brown and Jones, 2005) Subcutaneous • Sustained/controlled release from site of injection • Maintenance of plasma concentrations and more favorable pharmacokinetics • Decreases injection frequency (Prisell et al., 1992; Esposito et al., 2005; Kim et al., 2005) Intra-articular
• Retention of drug within the joint • Beneficial biological activities include the anti-inflammatory, analgesic and chondroprotective properties of HA (Rydell and Balazs, 1971; Marshall, 2000) Ocular • The shear-thinning properties of HA hydrogels mean minimal effects on visual acuity and minimal resistance to blinking • Mucoadhesion and prolonged retention time increase drug bioavailability to ocular tissues (Kaur and Smitha, 2002 , Wysenbeek et al., 1988 ,(Sintzel et al., 1996 Nasal • Mucoadhesion, prolonged retention time, and increased permeability of mucosal epithelium increase bioavailability (Lim et al., 2000; Turker et al., 2004; Ugwoke et al., 2005) Oral • Protects the drug from degradation in the GIT • Promotes oral bioavailability (Necas et al., 2008) J. Pharm. Invest., Vol. 40, No. Special issue (2010) overcome the challenge of poor bioavailability. The mucoadhesive properties of HA could enhance the absorption of drugs and proteins via mucosal tissues (Lim et al., 2000; Cho et al., 2003; Ludwig, 2005) as reported in the case where SA solution resulted in enhanced nasal absorption of vasopressin (Morimoto et al., 1991) . A study conducted in sheep, HA ester microspheres of insulin for the nasal delivery resulted in a significant increase in drug absorption (Illum et al., 1994) . Moreover, a bioadhesive delivery system for the intranasal administration of a flu vaccine which comprised of esterified hyaluronic acid (HYAFF) microspheres in combination with a mucosal adjuvant (LTK63) was also reported to be effective (Singh et al., 2001) . Also, a formulation of microparticles prepared by the spray dry method using HA-based microspheres containing PEG 6000 and/or sodium taurocholate for the nasal delivery of fexofenadine hydrochloride was able to enhance the AUC and Cmax values (Huh et al., 2010) .
The mucoadhesive property can be increased by conjugating HA with other bioadhesive polymers. Lim et al. was able to increase drug absorption by preparing biodegradable microparticles of gentamicin using chitosan (CH) and HA by the solvent evaporation method (Lim et al., 2000) . On the other hand, when HA is grafted with poly (ethylene glycol) (PEG-g-HA), PEG works as a drug reservoir in biodegradable HA. This matrix could prevent drug leakage and achieve degradationcontrolled insulin release (Moriyama et al., 1999) .
A nanocarrier composed of HA and CH was reported to encapsulate bovine serum albumin (BSA) and cyclosporine A for the nasal delivery of macromolecules (de la Fuente et al., 2008a) . Combination of absorption enhancer materials and bioadhesive polymers such as Cremophor RH 40 and SA could potentially increase the delivery of drugs, including peptide size molecules, into the CNS via the olfactory pathway (Horvat et al., 2009 ).
Parenteral Delivery Using HA
HA for sustained release of protein Therapeutic proteins are becoming an important source of medicine. Since the establishment of recombinant DNA technology which made it possible to produce large-scale of recombinant proteins, several therapeutic proteins have been approved and marketed for the treatment of various illnesses, including some diseases which were previously incurable. HA has been shown to be useful for SR formulations of protein and peptide drugs (Elbert et al., 2001 ) after parenteral delivery. While conventional drug delivery systems using poly-lactic glycolic acid (PLGA) exhibited inflammation and protein denaturation associated with the degradation of PLGA (Laurent, 1998) , HA appeared to be a protein-friendly drug carrier.
In 1992, Prisell et al. dissolved human insulin like growth hormone-I (hIGF-I) in HA solution and found that HA can be used for SR of protein (Prisell et al., 1992) . Later, sponge and hydrogel systems using HA blended with collagen was reported to be effective for the SR of human growth hormone (hGH) (Cascone and Sim, 1995) . More studies thereafter were conducted for the SR of insulin through the nasal route for treatment of diabetes (Moriyama et al., 1999; Surendrakumar et al., 2003; Ohri et al., 2004) .
The first SR formulation of recombinant human growth hormone (Nutropin ® Depot) prepared using PLGA was launched in 1999 in the United States. Unfortunately, patient compliance was a problem eventually leading to withdrawal of Nutropin ® Depot from the market in 2004 (Johnson et al., 1996; Herbert et al., 1998; Tracy, 1998) . Problems included scale-up difficulties, pain from injection and denaturation of the human growth hormone due to the hydrophobic interaction with PLGA and acidic environment created by disintegrating of PLGA. Thus, attention has been placed on HA for developing a SR formulation of human growth hormone using HA. Microparticle formulation using Hyaff11p50, where 50% of the carboxyl groups of HA are esterified with benzyl alcohol, was prepared by the solvent evaporation method and the spray dry method for a 7-day release of hGH (Esposito et al., 2005) . Figure 1 shows the scheme of the SR-rhGH preparation by the solvent evaporation method. Growth hormone was dissolved in water, which was added to mineral oil dropwise that contained Span 85. After stirring the mixture, the oil phase was washed. However, the solvent evaporation method resulted in the significant denaturation of hGH by oil phase and produced too big size particles thereby resulting in low patient compliance. One the other hand, a formulation of hGH/HA/lecithin by the spray dry method resulted in small particles that could be injected easily through a 26-gauge needle resulting in increasing patient compliance (Figure 2 ). This formulation was developed and launched exclusively in Korea by LG Life Science (Seoul, Korea) in 2007 which is the only SR-rhGH product currently available .
However, there was significant loss in the course of spray dry process and scale up. Thus, the current research is focused on making hydrogel of HA for the SR of protein drugs. HA derivatives, crosslinkers (Hahn et al., 2006) and conjugation with various polymers (Jeong et al., 2000; Hirakura et al., 2009; Lee et al., 2009) (2010) or synthetic polymers. Due to the hydrophilic nature of HA, hydrogels can provide an aqueous environment preventing proteins from denaturation (Hirakura et al., 2009) . Once inside the body, the gel precursors can crosslink physically due to the change in temperature (Jeong et al., 2000; Jeong et al., 2002) and pH (Shim et al., 2005) and chemically by Michael type addition reaction (Lutolf et al., 2003; Shim et al., 2005; Lee et al., 2006) and disulfide bond formation (Shu et al., 2002) . Kim et al. has reported on a HA/pluronic composite hydrogel which exhibited temperature-dependent swelling and collapse behaviors in aqueous solution. These hydrogels chemically degraded and eventually eroded as a result of hydrolytic scission of ester linkage in the structural unit of di-acryloyl pluronic component releasing the drug (Kim and Park, 2002) . Nevertheless, despite the facile procedure and minimized invasiveness of an injectable hydrogel system for the sustained delivery of proteins, a potential problem still exists. Slow gelation could cause a large amount of drugs to diffuse away from the injection site and lead to drug overdose. Thus, an attempt has been made to decrease gelation time by using HA-tyramine with proper amount of horseradish peroxidase and H 2 O 2 (Hirakura et al., 2009 ). However, because physically crosslinked hydrogel was very soft and easily disintegrated, an initial burst and rapid protein release resulted. Additionally, the chemically crosslinked hydrogel brought about protein denaturation during encapsulation . Thus, hybrid hyaluronan hydrogel encapsulating nanogel was developed to overcome the above mentioned problems. The nanogels were physically entrapped and well dispersed in a three-dimensional network of chemically cross-linked HA (HA gel). Therapeutic peptides and proteins, such as glucagon-like peptide-1, insulin and erythropoietin, were spontaneously trapped in the cholesteryl groupbearing pullulan (CHP) nanogels in the HA gel by immersing hybrid hydrogels into the drug solutions. The synergy between the CHP nanogel as a drug reservoir and the HA gel as a nanogel-releasing matrix of the hybrid hydrogel system simultaneously achieved both simple drug loading and controlled release with no denaturation of the protein drugs (Jeong et al., 2000) . Another type of susbtained formulation using HA is that which makes use of the electrostatic interaction between the negatively charged carboxylate groups of HA and the positive surface charge of Fe 2 O 3 nanoparticles forming a corral-like structure. The A549 and HEK 293 cell cultures were tested and found to be capable of taking in the HA particles and HAFe 2 O 3 hybrid nanoparticles, delivering the peptides into the cells and nucleus very efficiently (Kumar et al., 2007) . In another report, HA/N-carboxyethyl CH (CEC)/ BSA ternary complex by colloid titration with great quantitative precision had been prepared (Jiang et al., 2005) . The advantages of this ternary complex were facile formulation process, mild preparative conditions, high entrapment efficiency, biodegradable components, biocompatibility, pH-sensitivity, and extended release capability. On the other hand, porous microparticles (PMs) with a low density (<0.4 g/cm ) were prepared by the water-in-oil-in-water (W1/O/W2) multi-emulsion method using a cyclodextrin derivative as a porogen (Lee et al., 2007a) . The interaction of Lysine (Lys) and HA not only increased protein encapsulation efficiency but also stabilized Lys against a denaturing organic solvent (dichloromethane). Furthermore, PMs with Lys/HA complexes increased the Lys release period up to 7 days, as opposed to a 4 h Lys release time from PMs without Lys/HA complexes.
The high demand for SR formulation of protein is expected to continue because of the short biological half life of most protein drugs. The current commercial products make use of PLGA which is not water soluble. HA is thus still considered a promising candidate for these formulations due to its biocompatibility and water soluble property.
Gene delivery
Human gene therapy involves the insertion of genes, deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), into cells and biological tissues to treat gene defective diseases. Presently, most gene therapy studies are aimed at cancer related small interfering RNA (siRNA) by inhibition of oncogene expression. However, poor intracellular uptake, insufficient endosomal escape of genes and rapid enzymatic degradation of nucleic acid limit the efficiency of gene therapy (Edelstein et al., 2004; Schiffelers et al., 2004; Wilson et al., 2005) .
The use of synthetic nanocarrier with various cationic polymers, polypeptides and lipid has been recently proposed as a promising alternative for genes delivery. HA has been introduced as a nanocarrier for gene delivery since 2003 . Anionic nucleic acid drug by electrostatic binding or self assembly with DNA or genes form complex nanoparticles that are capable of being endocytosed by cells. However, low level of transfection and expression due to non-specific interaction between cationic complex and serum protein in the body have been barriers for gene therapy (Goldman et al., 1997) . Moreover, the strong positive surface charge, especially polyethyleneimine (PEI), have caused severe cytotoxicity (Fis- , 2003) . The DNA-HA matrix crosslinking with adipic dihydrazide (ADH) was able to sustain gene release while protecting the DNA from enzymatic degradation.
HA has also been used as HA-ADH hydrogel conjugated with an antigen for cell-specific targeting (Yun el al., 2004) . In addition, photocrosslinking pluronic hydrogel where the vinyl group of Pluronic TM was modified with HA (Chun et al., 2005) , crosslinking HA film with DNA incorporated within its structure (Kim, 2005) , photocrosslinking acryl-modified HA hydrogel (Wieland et al., 2007) and CH -DNA complexes incorporated into the multilayer via layer-by-layer deposition with HA (Lin et al., 2009 ) have been reported. To enhance gene delivery for tissue engineering, immobilized DNA/PEI complexes in HA-collagen hydrogel using biotin/neutravidin was fabricated with the ability to transfect adherent cells (Segura, 2005) . The biocompatibility of the anionic polysaccharide HA is achieved by shielding the positive surface of gene/polycation complexes and by inhibiting non-specific binding to serum proteins, thereby reducing the cytotoxicity of cationic polymers. HA combined with PEI (Ito et al., 2006; Saraf et al., 2008; Xu et al., 2009) , poly(L-lysine) (PLL) (Takei et al., 2004) , CH (de la Fuente et al., 2008b) , poly(L-arginine) (PLR) , and liposome (Chono et al., 2008) have been reported. HA coated to the surface of DNA/PEI complexes and HA-PEI conjugation has especially been widely studied as showed in Figure 5 . Ito et al. (Ito et al., 2006) synthesized conjugated spermine-HA which could mimic HMG (High Mobility Group) protein which has amphoteric structure, for loosening interaction between DNA/PEI and higher releasing free DNA. DNA/PEI/HA small complexes (<70 nm) for preventing aggregation of the complexes through freezedrying was also reported (Ito et al., 2010) .
Another use of HA was for target specific intracellular delivery of gene. CD44 and RHAMM have been identified as receptors of HA which were over-expressed in tumor or cancer cells. Figure 6 shows HA binding to the receptor on the cell surface and being intracellularly up-taken to the cell with increasing gene transfection efficiency. The comb-type polycation (PLL) having HA side chains has been synthesized for targeting foreign DNA to sinusoidal endothelial cells in liver (Takei et al., 2004) . In addition, DNA/PEI/HA ternary complex has been formulated for target specific delivery of DNA. It showed higher transfection and efficiency and lower cytotoxicity than DNA/PEI binary complex in malignant breast cancer cells with high CD44 level (Sun et al., 2009 ). Furthermore, low molecular weight HA (<10kDa) showed higher stability and transfection efficacy than high molecular weight HA (Hornof et al., 2008) . PEI-HA conjugate also was developed for siRNA delivery. The siRNA/PEI-HA complex was more efficient in LYVE-1 receptors B16F1 cells than in HEK-293 cells without HA receptor and provided higher levels of siRNA delivery than did the physical mixture of HA and PEI (Han et al., 2009) . Also, the siRNA/PEI-HA complexes exhibited higher gene silencing efficiency reducing VEGF production which resulted in tumor growth inhibition (Jiang et al., 2009) .
In another formulation, HA nanogels with thiol-conjugated HA has been synthesized where siRNA was encapsulated by inverse water-in-oil method. The release rate of siRNA was J. Pharm. Invest., Vol. 40, No. Special issue (2010) modulated by the concentration of glutathione (GSH) and the HA nanogels were transported into the cells mainly by CD44 receptor mediated endocytosis compared with negative cell lines (Lee et al., 2007b) . In addition, the thiol-modified HA was covalently conjugated to oligodeoxynucleotide (ODN) via disulfide linkage for increasing the charge density of ODN and then complexed with protamine, as a cationic polypeptide to form more stable polyelectrolyte complexes comparing to naked ODN (Mok et al., 2007) . Target specific gene delivery using HA also include lipoplexes containing HA conjugated to dioleoylphosphatidylethanolamine (DOPE) to target the CD44 receptor on breast cancer cells (Surace et al., 2009) . Therefore, the advantages of HA for genes delivery not only include SR properties, enhanced serum stability and reduced cytotoxicity but also target specific delivery with gene silencing efficiency.
Target specific delivery of antitumor drug HA is one of the major components of the extracellular matrix and is the main ligand for CD44 and RHAMM, which are over-expressed in a variety of tumor cell surfaces (Culty et al., 1994) including human breast epithelial cells (Bourguignon et al., 2000) , colon cancer (Catterall et al., 1999) , lung cancer (Matsubara et al., 2000) and acute leukemia (Yokota et al., 1999) cells. Therefore, anticancer drug targeting to tumor cells and tumor metastases can be accomplished by HA polymer drug conjugates via the HA receptor-mediated uptake of these drugs (Akima et al., 1996) . Furthermore, anticancer drugs coupled to HA can provide advantages in drug solubilization, stabilization, localization and controlled release (Maeda et al., 1992) .
The HA conjugates containing anticancer drugs include sodium butyrate (Coradini et al., 1999) , cisplatin (Xie et al., 2010) , doxorubicin , paclitaxel (Auzenne et al., 2007) and mitomycin C (Peer and Margalit, 2004) . Depending on the degree of substitution of HA with drugs, these exhibited enhanced targeting ability to the tumor and higher therapeutic efficacy compared to free-anticancer drugs. HA receptor targeted liposomes (HALs) were also developed which could target drug-containing liposomes to tumor cell that express CD44 (Eliaz and Szoka Jr, 2001) .
Amphiphilic HA derivatives capable of self-assembly to form nanoparticles as drug carriers were also formulated. . It was composed of hydrophobically modified HA derivatives with 5β-cholanic acid, the hydrophobic core of nanoparticles for encapsulating various anticancer drugs. Amphiphilic poly-peptide-block-polysaccharide copolymer based polymersomes loaded with doxorubicin by the nanoprecipitation method has also been reported (Upadhyay et al., 2010) .
Conclusion and Prospect
HA is a biodegradable, biocompatible, non-toxic, nonimmunogenic and non-inflammatory linear polysaccharide which is of interest to pharmaceutical scientists for the delivery of various drugs. HA or HA derivatives are being investigated for various formulations including those where HA is being conjugated with other polymers. What is of special interest is J. Pharm. Invest., Vol. 40, No. Special issue (2010) the SR formulations using HA. Microparticle, hydrogel and nanogel-releasing matrix of the hybrid hydrogel have been and are continuously being explored in this aspect. An ideal SR formulation of protein would need to be able to maintain the initial burst concentration for more than 7 days while being small in particle size enough to be injected through a 26-gauge needle. Also, reducing possible toxicity due to HA is an important consideration when developing novel formulations.
The advantage of HA formulations is seen in cancer therapy since HA specifically binds to the CD44 receptor which is overexpressed in several cancers. However, target specific gene therapy as well as controlled drug targeting still needs to overcome the problem of increasing intracellular uptake for future in vivo therapy. It is therefore expected that more HA related formulations will be studied and developed in the future as target specific drug delivery systems.
